Soluble TNF-Like weak inducer of apoptosis as a new marker in preeclampsia: A pilot clinical study
AuthorYıldırım Kayaoğlu, Zeynep
MetadataShow full item record
CitationYıldırım Kayaoğlu, Z., Sümnü, A., Bademler, N., Kılıç, E., Sümnü, G., Karadağ, S. ... Öztürk, S. (2016). Soluble TNF-Like weak inducer of apoptosis as a new marker in preeclampsia: A pilot clinical study. Disease Markers. https://dx.doi.org/10.1155/2016/5930589
Introduction. All findings of preeclampsia appear as the clinical consequences of diffuse endothelial dysfunction. Soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) was recently introduced as a TNF related cytokine in various inflammatory and noninflammatory disorders. sTWEAK was found to be related to endothelial dysfunction in patients with chronic kidney disease. In our study we aimed to compare sTWEAK levels in women with preeclampsia to corresponding levels in a healthy pregnant control group. Materials and Methods. The study was undertaken with 33 patients with preeclampsia and 33 normal pregnant women. The concentration of sTWEAK in serum was calculated with an enzyme linked immunosorbent assay (ELISA) kit. Results. Serum creatinine, uric acid, LDH levels, and uPCR were significantly higher in the patient group compared to the control group. sTWEAK levels were significantly lower in preeclamptic patients (332 +/- 144 pg/mL) than in control subjects (412 +/- 166 pg/mL) (p = 0.04). Discussion. Our study demonstrates that sTWEAK is decreased in patients with preeclampsia compared to healthy pregnant women. There is a need for further studies to identify the role of sTWEAK in the pathogenesis of preeclampsia and to determine whether it can be regarded as a predictor of the development of preeclampsia.